Clinical Physiology of Circulation

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Лечение хронической ишемии нижних конечностей с использованием стимуляторов неоангиогенеза

E-mail: Сведения доступны для зарегистрированных пользователей.

Link: Clinical Physiology of Blood Circulaiton. 2013; (): -

Full text:  

Abstract

Objective. To present the results of angiogenesis stimulators (genetic agent of growth factor of endothelioblasts VEGF165 of a human and autologous precursor cells of endothelioblasts CD 133+) in patients with chronic ischemia of lower limbs.
Material and methods. The study included 66 patients. The patients had single injection either genetic agent of growth factor of endothelioblasts VEGF165 of a human either autologous precursor cells of endothelioblasts CD 133+. No add-on therapy was carried out. The monitoring survey was in 1, 3, 6, 12 months after introduction of angiogenesis stimulator. Transcutaneous monitoring oxygen tension on the foot, ultrasonography of arteries of lower limbs, treadmill test, laser doppler flowmetry, angiographic study of lower limbs were used in the study. Properties of blood clot were estimated. The patients filled in SF 36 Quality of Life Questionnaire (the 1st version).
Results. Almost all the patients had clinical improvement after the introduction of angiogenesis stimulator in 3 months. Transcutaneous monitoring oxygen tension on the foot, index of pressure in malleolar, length of walking, number of collateral vessels according to angiography. The variables of microcirculation in the limb and quality of life of patients were improved.
Conclusion. Stimulators of angiogenesis showed moderate efficacy. Clinical improvement comes with delay so marked trophic disturbances is a contradiction to their isolated appliance.

References

Бокерия Л.А., Еремеева М.В. Современное состояние и перспективы использования ангиогенеза в лечении ишемической болезни сердца // Грудная и серд.-сосуд. хир. 2000. № 2. С. 57-61.
Бурлева Е.П. Критическая ишемия нижних конечностей: современные клинические и управленческие подходы: Автореф. дис. … д-ра мед. наук. М., 2003. 43 с.
Лазаренко В.Л., Симоненков А.Б., Лазарев Е.В. Лечение критической ишемии нижних конечностей с использованием серотонина // Ангиол. и сосуд. хир. 2003. № 2. С. 26-30.
Межобщественный согласительный документ по ведению пациентов с заболеванием периферических артерий (ЗПА) (TASC II) // Ангиол. и сосуд. хир. 2009. № 3. С. 50.
Савельев В.С., Кошкин В.М. Критическая ишемия нижних конечностей. М.: Медицина, 1997. 160 с.
Baumgartner I., Pieczek А. Constitutive Expression of phVEGF 165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia // Circulation. 1998. Vol. 97. P. 1114-1123.
Folkman J. Terapeutic angiogenesis in ischemic limb // Circulation. 1998. Vol. 97. P. 1108-1110.
Folkman J. Tumor angiogenesis: Therapeutic implications // N. Engl. J. Med. 1971. Vol. 285. P. 1182-1186.
Heilmann C., Beyersdorf F., Lutter G. Collateral growth: Cell arrive at the construction site // Cardiovasc. Surg. 2002. Vol. 10. P. 570-578.
Tateishi-Yuyama E., Matsubara H. Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial // Lancet. 2002. Vol. 360. P. 427-435.

 If you found mistakes, select text and press Alt+A